全文获取类型
收费全文 | 442394篇 |
免费 | 61679篇 |
国内免费 | 26011篇 |
专业分类
耳鼻咽喉 | 5645篇 |
儿科学 | 6112篇 |
妇产科学 | 7352篇 |
基础医学 | 44414篇 |
口腔科学 | 10859篇 |
临床医学 | 73630篇 |
内科学 | 75779篇 |
皮肤病学 | 6566篇 |
神经病学 | 30915篇 |
特种医学 | 16612篇 |
外国民族医学 | 221篇 |
外科学 | 53338篇 |
综合类 | 56966篇 |
现状与发展 | 124篇 |
一般理论 | 22篇 |
预防医学 | 34555篇 |
眼科学 | 12218篇 |
药学 | 36966篇 |
364篇 | |
中国医学 | 19747篇 |
肿瘤学 | 37679篇 |
出版年
2024年 | 1491篇 |
2023年 | 9653篇 |
2022年 | 15023篇 |
2021年 | 20421篇 |
2020年 | 18313篇 |
2019年 | 13597篇 |
2018年 | 18925篇 |
2017年 | 18012篇 |
2016年 | 17795篇 |
2015年 | 23406篇 |
2014年 | 29403篇 |
2013年 | 28854篇 |
2012年 | 28735篇 |
2011年 | 31680篇 |
2010年 | 24451篇 |
2009年 | 22713篇 |
2008年 | 22021篇 |
2007年 | 20980篇 |
2006年 | 21929篇 |
2005年 | 20051篇 |
2004年 | 12865篇 |
2003年 | 11502篇 |
2002年 | 9996篇 |
2001年 | 9781篇 |
2000年 | 9846篇 |
1999年 | 11055篇 |
1998年 | 7650篇 |
1997年 | 7515篇 |
1996年 | 6407篇 |
1995年 | 5714篇 |
1994年 | 4393篇 |
1993年 | 3055篇 |
1992年 | 3623篇 |
1991年 | 3109篇 |
1990年 | 2672篇 |
1989年 | 2414篇 |
1988年 | 2094篇 |
1987年 | 1699篇 |
1986年 | 1456篇 |
1985年 | 1205篇 |
1984年 | 783篇 |
1983年 | 664篇 |
1982年 | 468篇 |
1981年 | 438篇 |
1980年 | 304篇 |
1979年 | 287篇 |
1978年 | 212篇 |
1977年 | 208篇 |
1974年 | 176篇 |
1972年 | 157篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
12.
痛情绪是指因疼痛引发的情绪和情感体验,是疾病过程中最常见的一种情绪。痛情绪相关神经机制非常复杂,但主要与单胺类神经递质、神经肽和某些神经环路有关,笔者将结合目前研究现状分别从以上两方面展开,就痛情绪相关单胺类神经递质和神经肽在受体分类、脑区通路、共疾病以及各神经递质之间的联系和痛情绪相关神经环路中各个蛋白的作用机制等方面进行探讨。 相似文献
13.
14.
Wuteng Cao Huabin Hu Jiao Li Qianyu Wu Lishuo Shi Biao Li Jie Zhou Xinhua Wang Junhong Chen Chao Wang Huaiming Wang Weihao Deng Yan Huang Yanhong Deng 《International journal of cancer. Journal international du cancer》2023,153(11):1894-1903
Neoadjuvant programmed cell death protein 1 (PD-1) blockade exhibits promising efficacy in patients with mismatch repair deficient (dMMR) colorectal cancer (CRC). However, discrepancies between radiological and histological findings have been reported in the PICC phase II trial (NCT 03926338). Therefore, we strived to discern radiological features associated with pathological complete response (pCR) based on computed tomography (CT) images. Data were obtained from the PICC trial that included 36 tumors from 34 locally advanced dMMR CRC patients, who received neoadjuvant PD-1 blockade for 3 months. Among the 36 tumors, 28 (77.8%) tumors achieved pCR. There were no statistically significant differences in tumor longitudinal diameter, the percentage change in tumor longitudinal diameter from baseline, primary tumor sidedness, clinical stage, extramural venous invasion status, intratumoral calcification, peritumoral fat infiltration, intestinal fistula and tumor necrosis between the pCR and non-pCR tumors. Otherwise, tumors with pCR had smaller posttreatment tumor maximum thickness (median: 10 mm vs 13 mm, P = .004) and higher percentage decrease in tumor maximum thickness from baseline (52.9% vs 21.6%, P = .005) compared to non-pCR tumors. Additionally, a higher proportion of the absence of vascular sign (P = .003, odds ratio [OR] = 25.870 [95% CI, 1.357-493.110]), nodular sign (P < .001, OR = 189.000 [95% CI, 10.464-3413.803]) and extramural enhancement sign (P = .003, OR = 21.667 [2.848-164.830]) was observed in tumors with pCR. In conclusion, these CT-defined radiological features may have the potential to serve as valuable tools for clinicians in identifying patients who have achieved pCR after neoadjuvant PD-1 blockade, particularly in individuals who are willing to adopt a watch-and-wait strategy. 相似文献
15.
目的探讨脊髓小脑共济失调2型(SCA2)致病基因ATXN2异常等位基因中间重复个体的表型和分子遗传学特点。方法针对2005—2018年中日友好医院神经科运动障碍与神经遗传病研究中心收集的1383个常染色体显性遗传共济失调家系的先证者和部分家系成员,采用荧光标记毛细管电泳片段分析方法进行动态突变检测,对携带ATXN2基因中间重复的个体进行临床表型和遗传特征分析。结果共检出163个家系(包含先证者和家系成员共203人)携带异常扩展的ATXN2基因CAG重复序列,其中93个家系中有107例的异常扩展等位基因重复次数在29~34次之间。在其中的20个亲子对中,父系遗传16个,异常等位基因的代间扩展增加0~28次,母系遗传4个,异常等位基因的代间扩展增加0~4次。结论对于临床拟诊SCA2家系患者,需对其亲代或成年子代个体进行ATXN2基因检测,以免漏诊。动态突变基因检测有助于识别中间重复的个体,对明确家系致病基因和遗传咨询至关重要。 相似文献
16.
Zeyu Li Erwei Hao Rui Cao Si Lin Linghui Zou Tianyan Huang Zhengcai Du Xiaotao Hou Jiagang Deng 《中草药(英文版)》2022,14(4):479-493
Zedoary tumeric (Curcumae Rhizoma, Ezhu in Chinese) has a long history of application and has great potential in the treatment of liver cancer. The anti liver cancer effect of zedoary tumeric depends on the combined action of multiple pharmacodynamic substances. In order to clarify the specific mechanism of zedoary tumeric against liver cancer, this paper first analyzes the mechanism of its single pharmacodynamic substance against liver cancer, and then verifies the joint anti liver cancer mechanism of its "pharmacodynamic group". By searching the research on the anti hepatoma effect of active components of zedoary tumeric in recent years, we found that pharmacodynamic substances, including curcumol, zedoarondiol, curcumenol, curzerenone, curdione, curcumin, germacrone, β-elemene, can act on multi-target and multi-channel to play an anti hepatoma role. For example, curcumin can regulate miR, GLO1, CD133, VEGF, YAP, LIN28B, GPR81, HCAR-1, P53 and PI3K/Akt/mTOR, HSP70/TLR4 and NF-κB. Wnt/TGF/EMT, Nrf2/Keap1, JAK/STAT and other pathways play an anti hepatoma role. Network pharmacological analysis showed that the core targets of the "pharmacodynamic group" for anti-life cancer are AKT1, EGFR, MAPK8, etc, and the core pathways are neuroactive live receiver interaction, nitrogen metabolism, HIF-1 signaling pathway, etc. At the same time, by comparing and analyzing the relationship between the specific mechanisms of pharmacodynamic substance and "pharmacodynamic group", it is found that they have great reference significance in target, pathway, biological function, determination of core pharmacodynamic components, formation of core target protein interaction, in-depth research of single pharmacodynamic substance, increasing curative effect and so on. By analyzing the internal mechanism of zedoary tumeric pharmacodynamic substance and "pharmacodynamic group" in the treatment of liver cancer, this paper intends to provide some ideas and references for the deeper pharmacological research of zedoary tumeric and the relationship between pharmacodynamic substance and "pharmacodynamic group". 相似文献
17.
18.
19.
20.
Her-Shyong Shiah Nai-Jung Chiang Chia-Chi Lin Chia-Jui Yen Hui-Jen Tsai Shang-Yin Wu Wu-Chou Su Kwang-Yu Chang Ching-Chiung Wang Jang-Yang Chang Li-Tzong Chen 《The oncologist》2021,26(4):e567-e579
Lessons Learned
- SCB01A is a novel microtubule inhibitor with vascular disrupting activity.
- This first‐in‐human study demonstrated SCB01A safety, pharmacokinetics, and preliminary antitumor activity.
- SCB01A is safe and well tolerated in patients with advanced solid malignancies with manageable neurotoxicity.